While human melanoma in the TCGA shows a reverse relationship between G9a expression levels and immune signature genes, mouse studies in melanoma found that G9a inhibition, in combination with anti-PD-1 or anti-CTLA-4, increased survival compared to immunotherapy alone [21]. The gene discussed is EHMT2; the disease is melanoma.